This case series highlights the genotypic and phenotypic heterogeneity of homozygous familial hypercholesterolemia and the partial efficacy of advanced lipid-lowering therapies in these patients.
Abstract Background Familial hypercholesterolaemia (FH) is an inherited lipid disorder characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels and increased risk of atherosclerotic cardiovascular disease. Despite its high prevalence, FH remains underdiagnosed and undertreated in many regions, particularly in low- and middle-income countries. Case summary We describe two patients with homozygous FH (HoFH) diagnosed at a tertiary care centre using the Dutch Lipid Clinic Network diagnostic criteria, both presented with severe hypercholesterolaemia (LDL-C 340 mg/dL) and tendon xanthomas, whereas early cardiovascular complications were evident only in case 1. Genetic analysis confirmed pathogenic variants in LDLR: c.1060+2TG (rs774069731) in case 1 and c.530CT (rs121908026) in case 2. The patients were managed with high-intensity statins, ezetimibe, PCSK9 inhibitors, inclisiran, and lipoprotein apheresis, which resulted in partial LDL-C reduction. Discussion These cases highlight the genotypic and phenotypic heterogeneity of FH, with the c.1060+2TG variant being reported for the first time in this region, thus expanding the known genetic spectrum of FH. Conclusion This case series reinforces the importance of comprehensive clinical and genetic evaluation in patients with severe hypercholesterolaemia. Early diagnosis, intensified lipid-lowering strategies, and equitable access to advanced therapies are essential to improve outcomes in resource-constrained settings.
Sahoo et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: